Neurotransmitter interactions in schizophrenia--therapeutic implications (Q33782626)

29 July 2017

1 reference

title

Neurotransmitter interactions in schizophrenia--therapeutic implications (English)

1 reference

29 July 2017

0 references

1 reference

Carlsson A

1

1 reference

29 July 2017

Waters N

series ordinal

2

1 reference

29 July 2017

Carlsson ML

series ordinal

3

1 reference

29 July 2017

language of work or name

English

0 references

publication date

1 November 1999

1 reference

29 July 2017

published in

Biological Psychiatry

1 reference

29 July 2017

volume

46

1 reference

29 July 2017

issue

10

1 reference

29 July 2017

page(s)

1388-1395

1 reference

Low brain uptake of L-[11C]5-hydroxytryptophan in major depression: a positron emission tomography study on patients and healthy volunteers.

29 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900117-1

Functional architecture of basal ganglia circuits: neural substrates of parallel processing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900117-1

Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900117-1

The current status of the dopamine hypothesis of schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900117-1

The selective 5-HT2A receptor antagonist MDL 100,907 counteracts the psychomotor stimulation ensuing manipulations with monoaminergic, glutamatergic or muscarinic neurotransmission in the mouse--implications for psychosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900117-1

The NMDA antagonist MK-801 causes marked locomotor stimulation in monoamine-depleted mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900117-1

Interactions between glutamatergic and monoaminergic systems within the basal ganglia-implications for schizophrenia and Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900117-1

Interfering with glutamatergic neurotransmission by means of NMDA antagonist administration discloses the locomotor stimulatory potential of other transmitter systems

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900117-1

The 5-HT2A receptor antagonist M100907 is more effective in counteracting NMDA antagonist- than dopamine agonist-induced hyperactivity in mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900117-1

Presynaptic dopaminergic function in the striatum of schizophrenic patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900117-1

Evidence for biochemical heterogeneity in schizophrenia: a multivariate study of monoaminergic indices in human post-mortal brain tissue

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900117-1

On the quantitative structure-activity relationships of meta-substituted (S)-phenylpiperidines, a class of preferential dopamine D2 autoreceptor ligands: modeling of dopamine synthesis and release in vivo by means of partial least squares regression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900117-1

Striatal D2 dopamine receptor characteristics in neuroleptic-naive schizophrenic patients studied with positron emission tomography

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900117-1

Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900117-1

Antipsychotic properties of the partial dopamine agonist (-)-3-(3-hydroxyphenyl)-N-n-propylpiperidine(preclamol) in schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900117-1

Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900117-1

Rodent data and general hypothesis: antipsychotic action exerted through 5-Ht2A receptor antagonism is dependent on increased serotonergic tone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900117-1

Effects of MK-801 on spontaneous and amphetamine-stimulated dopamine release in striatum measured with in vivo microdialysis in awake rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900117-1

Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900117-1

The role of 5-HT2A receptors in antipsychotic activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900117-1

Substituted (S)-phenylpiperidines and rigid congeners as preferential dopamine autoreceptor antagonists: synthesis and structure-activity relationships.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900117-1

(+)-UH 232 and (+)-UH 242: novel stereoselective dopamine receptor antagonists with preferential action on autoreceptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900117-1

Muscimol: GABA agonist therapy in schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900117-1

Concurrent locomotor stimulation and decrease in dopamine release in rats and mice after treatment with the competitive NMDA receptor antagonists D-CPPene and CGS 19755

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900117-1

10.1016/S0006-3223(99)00117-1

7 January 2021

Identifiers

DOI

1 reference

29 July 2017

1 reference